Brokerages Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80

Shares of Immuneering Co. (NASDAQ:IMRX) have received an average recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $12.80.

IMRX has been the topic of a number of recent analyst reports. Morgan Stanley downgraded shares of Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price objective on shares of Immuneering in a report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of Immuneering in a report on Monday.

Immuneering Stock Down 2.9 %

Shares of Immuneering stock opened at $2.01 on Thursday. The firm has a market capitalization of $62.41 million, a P/E ratio of -1.02 and a beta of -0.34. Immuneering has a 52 week low of $1.00 and a 52 week high of $7.68. The firm’s 50 day moving average is $2.05 and its two-hundred day moving average is $1.78.

Institutional Trading of Immuneering

A number of hedge funds have recently added to or reduced their stakes in IMRX. Acadian Asset Management LLC acquired a new position in shares of Immuneering in the second quarter valued at approximately $67,000. Renaissance Technologies LLC purchased a new position in Immuneering in the 2nd quarter valued at $447,000. XTX Topco Ltd increased its stake in Immuneering by 37.3% in the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares during the period. Marshall Wace LLP purchased a new position in Immuneering during the 2nd quarter worth $492,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Immuneering in the 2nd quarter worth $44,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.